This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/mesh/concept/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01764/identifier/chemspider/
n19http://linked.opendata.cz/resource/drugbank/mixture/
n18http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB01764/identifier/wikipedia/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01764/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01764/identifier/kegg-compound/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01764/identifier/pdb/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01764/identifier/pubchem-compound/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01764/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01764/identifier/kegg-drug/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01764/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB01764
rdf:type
n3:Drug
n3:description
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
n3:generalReferences
# Allington DR, Rivey MP: Quinupristin/dalfopristin: a therapeutic review. Clin Ther. 2001 Jan;23(1):24-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11219478 # Lamb HM, Figgitt DP, Faulds D: Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999 Dec;58(6):1061-97. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10651391 # Manzella JP: Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Am Fam Physician. 2001 Dec 1;64(11):1863-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11764864 # Paradisi F, Corti G, Messeri D: Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am. 2001 Jan;85(1):1-17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11190346
n3:group
approved
n3:halfLife
The elimination half-life is approximately 0.70 hours.
n3:indication
For the treatment of bacterial infections (usually in combination with quinupristin).
owl:sameAs
n12:DB01764 n18:DB01764
dcterms:title
Dalfopristin
adms:identifier
n8:PA164746234 n9:21943991 n10:D00853 n13:DOL n14:C08033 n15:4940480 n16:DB01764 n17:Dalfopristin n20:46506561
n3:mechanismOfAction
The site of action of dalfopristin is the bacterial ribosome. Dalfopristin has been shown to inhibit the early phase of protein synthesis.
n3:synonym
Dalfopristina Dalfopristinum Dalfopristine
n3:mixture
n19:271B446D-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Moderate
n5:hasConcept
n6:M0293796
n3:IUPAC-Name
n4:271B4472-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4478-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4477-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4474-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4475-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4476-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4470-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B446E-363D-11E5-9242-09173F13E4C5 n4:271B4471-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B446F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B447E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B447F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4479-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B447A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B447C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B447B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B447D-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Enterococcus faecalis Enteric bacteria and other eubacteria
n3:casRegistryNumber
112362-50-2
n3:category
n3:Bioavailability
n4:271B4484-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4486-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4487-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4483-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4482-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4485-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4473-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4480-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4481-363D-11E5-9242-09173F13E4C5